First-in-India experience with 90Y-BhabhaSphere: an indigenous 90Y-TheraSphere biosimilar for transarterial radioembolization of hepatic malignancies
British Journal of Radiology · 2025
DOI: 10.1093/bjr/tqaf197 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Radiology, 2025. Verfasst von Ashish Kumar Jha und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Tata Memorial Centre, Mumbai, Maharashtra, 400012, India. Hauptthemen laut MEDLINE: Liver Neoplasms, Yttrium Radioisotopes, Embolization, Therapeutic, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Objective
Primary and secondary hepatic malignancies are a significant cause of cancer-related mortality worldwide. Radioembolization with yttrium-90 (90Y) microspheres has emerged as a promising treatment option for unresectable hepatic tumours. However, the high cost of commercially available Y-90 microspheres, such as 90Y-TheraSphere or 90Y-SirSphere, limits their accessibility in developing countries. We present the first Indian clinical experience of indigenously developed [90Y] Yttria alumino silicate glass microspheres, known as “90Y-BhabhaSphere,” for radioembolization of hepatic malignancies. Methods “90Y-BhabhaSphere” formulation developed at Bhabha Atomic Research Centre (BARC), Mumbai, was used to treat a small cohort of 5 patients with unresectable hepatic malignancies. The 90Y-BhabhaSphere delivery system was developed through a rigorous process and in vitro tested using a microcatheter connection to simulate the transarterial radioembolization (TARE) procedure. Feasibility, safety, delivery efficiency, and preliminary efficacy of treatment using 90Y-BhabhaSphere were assessed.
Results
Our initial clinical experience with 90Y-BhabhaSphere demonstrates its safety and feasibility in treating hepatic malignancies. 90Y-BhabhaSphere demonstrated excellent delivery efficiency, reaching 99% in vitro (dummy run) and 97% in vivo (clinical delivery) 90Y-BhabhaSphere was successfully administered to 4 patients, whereas in 1 patient, the delivery had to be terminated due to a leakage in the delivery system. The treatment was well-tolerated, with minimal adverse effects. Preliminary efficacy analysis shows promising results, with a significant reduction in tumour size and improvement in liver function.
Conclusion
90Y-BhabhaSphere offers a cost-effective alternative to commercially available 90Y-microspheres. Our initial clinical experience demonstrates its safety, feasibility, and preliminary efficacy in treating hepatic malignancies. Large clinical trials need to be conducted to establish the long-term efficacy and safety of 90Y-BhabhaSphere. Advances in knowledge This study highlights a key advantage of 90Y-BhabhaSphere: its significantly higher specific activity (approximately 6000 Bq/sphere) compared to commercially available 90Y-TheraSphere (2700 Bq/sphere). This suggests a potential for delivering higher tumour doses while minimizing radiation exposure to healthy liver tissue, thereby reducing the risk of radiation-induced liver damage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Tata Memorial Centre, Mumbai, Maharashtra, 400012, India.
- Homi Bhabha National Institute, Mumbai, Maharashtra, 400094, India.
- Department of Radiology, Tata Memorial Hospital, Tata Memorial Centre, Mumbai, Maharashtra, 400012, India.
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra, 400085, India.
- Radiopharmaceutical Laboratory and Fission Moly Facility (RPL & FMP), Board of radiation and Isotope division (BRIT), Navi Mumbai, Maharashtra, 400703, India.
ORCID-Profile: Ashish Kumar Jha
Zitieren
APA
Jha, A. K., Puranik, A. D., Gala, K. B., Nair, K. V. V., Rajeswari, A., Lohar, S. P., Shah, A., Mathai, A. M., Tiwary, B. K., Shettye, N. S., Mathur, A., Pandey, U., Chakraborty, S., Purandare, N., Kulkarni, S., & Rangarajan, V. (2025). First-in-India experience with 90Y-BhabhaSphere: an indigenous 90Y-TheraSphere biosimilar for transarterial radioembolization of hepatic malignancies. British Journal of Radiology. https://doi.org/10.1093/bjr/tqaf197
Vancouver
Jha AK, Puranik AD, Gala KB, Nair KVV, Rajeswari A, Lohar SP, et al. First-in-India experience with 90Y-BhabhaSphere: an indigenous 90Y-TheraSphere biosimilar for transarterial radioembolization of hepatic malignancies. British Journal of Radiology. 2025. doi:10.1093/bjr/tqaf197
BibTeX
@article{Jha2025,
author = {Jha, Ashish Kumar and Puranik, Ameya D and Gala, Kunal Bharat and Nair, K V Vimalnath and Rajeswari, Ardhi and Lohar, Sharad P and Shah, Aaditya and Mathai, Amala M and Tiwary, Bikash K and Shettye, Nitin Sudhakar and Mathur, Anupam and Pandey, Usha and Chakraborty, Sudipta and Purandare, Nilendu and Kulkarni, Suyash and Rangarajan, Venkatesh},
title = {First-in-India experience with 90Y-BhabhaSphere: an indigenous 90Y-TheraSphere biosimilar for transarterial radioembolization of hepatic malignancies},
journal = {British Journal of Radiology},
year = {2025},
doi = {10.1093/bjr/tqaf197}
}
EUVIMED